The Growing Armamentarium Against EGFR Exon 20+ Non–Small Cell Lung Cancer
Joshua K. Sabari, MD, reviews the therapies available to treat patients with EGFR exon 20-positive non–small cell lung cancer.
Joshua K. Sabari, MD, assistant professor, Department of Medicine, NYU Grossman School of Medicine, reviews the therapies available to treat patients with EGFR exon 20-positive non–small cell lung cancer (NSCLC).
In recent years, there was an explosion of therapeutic opportunities for patients with EGFR exon 20 insertion mutant NSCLC, Sabari says. The two avenues of therapies are EGFR exon 20-directed tyrosine kinase inhibitors such as mobocertinib, which is a small molecule that specifically inhibits EGFR exon 20. Sabari explains that there are many other exon 20-specific TKIs in development, such as BDTX-189 and CLN-081. Older agents like poziotinib are also still effective for the treatment of this patient population.
Most recently, the FDA granted approval to amivantamab-vmjw (Rybrevant), an agent that has been shown to have activity in exon 20 insertion mutant disease.
Kim Evaluates New Regimens for EGFR+ Lung Cancer
January 20th 2025During a Community Case Forum event in partnership with the Medical Oncology Association of Southern California, Edward S. Kim, MD, MBA, discussed the FLAURA2 and MARIPOSA trials of newer regimens for EGFR-positive lung cancer.
Read More
Amivantamab/Lazertinib Maintains OS Benefit in EGFR+ NSCLC
January 15th 2025During a Case-Based Roundtable® event, Joshua K. Sabari, MD, continued discussion of key outcomes from the MARIPOSA trial and toxicity management in patients with EGFR-mutated non–small cell lung cancer in the second article of a 2-part series.
Read More
